Clinical Trials
4 trialsNCT07005102 2026-05-22
A Study to Assess Adverse Events, Change in Disease Activity of Intravenous Telisotuzumab Adizutecan in Combination With Osimertinib as First-Line Treatment in Adult Participants With Locally Advanced Unresectable or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer
AbbVie
Phase 2/3 Recruiting
NCT05020769 2025-09-26
SI-B001 Combined With Osimertinib Mesylate Tablets in the Treatment of Recurrent Metastatic Non-small Cell Lung Cancer.
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 2/3 Active not recruiting
NCT06908772 2025-04-03
Glumetinib Combined With Osimertinib Treatment for Non-Small Cell Lung Cancer Patients
Shanghai JMT-Bio Inc.
Phase 2/3 Not yet recruiting
NCT02959749 2018-02-14
Osimertinib or Docetaxel-bevacizumab as Third-line Treatment in EGFR T790M Mutated Non-Small Cell Lung Cancer
Qingdao Central Hospital
Phase 2/3 Completed